1. Home
  2. |Insights
  3. |Overview of Rules for Qualified Foreign Financial Institutions’ Investment in Listed Shares in Saudi Arabia

Overview of Rules for Qualified Foreign Financial Institutions’ Investment in Listed Shares in Saudi Arabia

Client Alert | 1 min read | 05.21.15

In July 2014, the Saudi Arabian Capital Market Authority (CMA) announced that it had been given approval to permit qualified foreign financial institutions (QFIs) to trade directly in shares listed on the Saudi Arabian Stock Exchange (the Tadawul), and that the CMA expected the Tadawul to be open to QFIs at some point during the first six months of 2015.

The CMA subsequently issued the Draft Rules for Qualified Financial Institutions' Investment in Listed Shares and invited interested parties to submit their comments and observations on the Draft Rules to the CMA no later than November 20, 2014. Having reviewed and considered the comments from interested parties about the Draft Rules, the CMA issued on May 4, 2015 the Rules for Qualified Foreign Financial Institutions' Investment in Listed Shares.

The CMA has confirmed that the opening of the Tadawul to foreign investors is intended to support the increased participation of institutional investors and reduce the role of retail investors. Financial institutions interested in trading in shares listed on the Tadawul should be aware of the formalities involved in securing the necessary regulatory consents, the ongoing requirements and the potential issues that still exist.

For an overview of the Rules, please click here to download a PDF.

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...